Cargando…
Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis
PURPOSE: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, key drivers of chronic inflammation. Bimekizumab must be injected subcutaneously and so patients require self-injection options that meet their preferences. This study evaluated s...
Autores principales: | Kivitz, Alan, Ellis, Alicia M, Shende, Vishvesh, Lambert, Jérémy, Tatla, Daljit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559892/ https://www.ncbi.nlm.nih.gov/pubmed/37808274 http://dx.doi.org/10.2147/PPA.S427809 |
Ejemplares similares
-
An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
por: Oliveira, Daniel G, et al.
Publicado: (2021) -
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023) -
Bimekizumab for plaque psoriasis
Publicado: (2022) -
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018) -
A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects
por: Bush, Jim, et al.
Publicado: (2019)